Biota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
April 12 2016 - 7:00AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the
Company has changed its name to Aviragen Therapeutics, Inc.,
(“Aviragen Therapeutics”), a pharmaceutical company focused on the
development of the next generation of direct-acting antivirals that
address infections that have limited therapeutic options.
“A meaningful transformation has taken place
over the last two years as we transitioned from a drug discovery
and early-stage licensing organization to one focused on drug
development and progressing key late-stage product candidates in
important viral diseases. Our name change reflects this transition
and better defines our strategic initiatives moving forward,” said
Joseph Patti, PhD, President and Chief Executive Officer of
Aviragen Therapeutics. “Specifically, our recent initiation of a
Phase 2a efficacy study of BTA585 for the treatment of RSV
infections highlights our focus on bringing new medicines to treat
and prevent viral infections with limited therapeutics options. As
Aviragen Therapeutics, we will continue to advance and expand our
promising pipeline of anti-viral drugs.”
The name change become effective on April 11,
2016 and the Company’s common stock will begin trading on the
NASDAQ Stock Exchange under the new ticker symbol “AVIR” on April
13, 2016. The Company will have a new website
address: www.aviragentherapeutics.com.
About Aviragen Therapeutics
Aviragen Therapeutics is focused on the
discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic
options and affect a significant number of patients globally. The
Company has three product candidates in active clinical
development: These include vapendavir, an oral treatment for human
rhinovirus upper (HRV) respiratory infections in moderate-to-severe
asthmatics currently being evaluated in the Phase 2b SPIRITUS
trial; BTA585, an oral fusion protein inhibitor which received Fast
Track designation by the U.S. FDA, in Phase 2 development for the
treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve known and unknown risks and
uncertainties concerning Aviragen Therapeutics’ business,
operations and financial performance. Any statements that are not
of historical facts may be deemed to be forward-looking statements.
Various important factors could cause actual results, performance,
events or achievements to materially differ from those expressed or
implied by forward-looking statements, including: the Company, the
U.S. Food and Drug Administration (FDA) or a similar regulatory
body in another country, a data safety monitoring board, or an
institutional review board delaying, limiting, suspending or
terminating the clinical development of any of the Company's
product candidates at any time for a lack of safety, tolerability,
regulatory or manufacturing issues, or any other reason whatsoever;
the Company's ability to secure, manage and retain qualified
third-party clinical research data management and contract
manufacturing organizations upon which it relies to assist in the
design, development, implementation and execution of the clinical
development of all its product candidates and those organizations’
ability to successfully execute their contracted responsibilities;
the Company’s ability to comply with applicable government
regulations in various countries and regions in which we are
conducting, or expect to conduct, clinical trials; and other
cautionary statements contained elsewhere in this press release and
in our Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and our other reports filed with the Securities and Exchange
Commission. There may be events in the future that the Company is
unable to predict, or over which it has no control, and the
Company’s business, financial condition, results of operations and
prospects may change in the future. The Company may not update
these forward-looking statements more frequently than quarterly
unless it has an obligation under U.S. Federal securities laws to
do so.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024